Collectionner le produit
Détails du produit
Source
Biotinylated Anti-Bevacizumab Antibody (AY13) is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.
Clone
AY13
Species
Mouse
Isotype
Mouse IgG1 | kappa
Antibody Type
Hybridoma Monoclonal
Reactivity
Human
Immunogen
Bevacizumab
Specificity
Recognizes Bevacizumab specifically.
Application
ApplicationRecommended UsageELISA1-100 ng/mLPurity
95% as determined by SDS-PAGE.
Purification
Protein A purified / Protein G purified
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
For best performance, we strongly recommend following the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Biotinylated Anti-Bevacizumab Antibody (AY13) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Detection of bevacizumab by bridging ELISA in serum. Immobilized Anti-Bevacizumab Antibody (AY10) (Cat. No. BEB-Y10) at 2 μg/mL, add increasing concentrations of bevacizumab (10% human serum) and then add Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13) at 2 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 0.4 μg/mL (QC tested).
Protocol
Immobilized bevacizumab at 1 μg/mL (100 μL/well) can bind Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13) with a linear range of 0.78-25.5 ng/mL.
Protocol
Serial dilutions of Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13) were added into Human VEGF165, premium grade (Cat. No. VE5-H4210): Human Anti-VEGFA(AVASTIN), Human IgG1 (D239E, L241M) | Human Kappa binding reactions. The half maximal inhibitory concentration (IC50) is 1.032 μg/mL (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
Contact Us
Drug Candidate Licensing
